Abstract: Bifidobacterium longum strain NCIMB 41676 is useful for improving or sustaining vitality and/or reducing mental fatigue in stressful situations.
Type:
Grant
Filed:
January 29, 2019
Date of Patent:
October 3, 2023
Assignee:
PrecisionBiotics Group Limited
Inventors:
Eileen Frances Murphy, Paul Enck, Christoph Braun, Huiying Wang
Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.
Abstract: The present invention relates to a method for the in vitro detection of a latent tuberculosis infection (LTBI) in a subject, wherein said method comprises determining at least one nucleotide sequence and/or at least one polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population of said subject, and wherein the presence of said at least one nucleotide sequence and/or said at least one polypeptide is indicative for said latent tuberculosis infection. In particular, the blood cell population is enriched for hematopoietic stem cells. The invention also relates to a pharmaceutical composition for use in the treatment of the LTBI in the subject, wherein it is determined if the nucleotide sequence and/or the polypeptide of Mtb is/are present in the blood cell population. Further, the invention relates to kits for carrying out the methods of the invention. The invention also relates to the use of the kits.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
September 26, 2023
Assignees:
Max-Planck-Gesellschaft, Medizinische Universität Wien
Inventors:
Julia Tornack, Stephen Reece, Fritz Melchers, Stefan H. E. Kaufmann, Wolfgang Bauer, Georg Stingl
Abstract: Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.
Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Type:
Grant
Filed:
June 3, 2022
Date of Patent:
September 26, 2023
Assignee:
Synlogic Operating Company, Inc.
Inventors:
Kristin Adolfsen, Per Greisen, Isolde Callihan, Adam Lawrence, James Spoonamore, Jay Konieczka
Abstract: This disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Abstract: The present invention relates to amino acid sequences that are directed against interleukin 23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODY® molecules against IL-23 and one NANOBODY® molecule against serum albumin, linked by two linkers. In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).
Abstract: The present invention concerns a method of cleaning and/or sanitizing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support. The method comprises the steps of: a) optionally purifying a mixture comprising a first immunoglobulin using the separation matrix; b) providing a cleaning liquid comprising at least 50% by volume of an aqueous alkali metal hydroxide solution; and c) cleaning and/or sanitizing the separation matrix by contacting the cleaning liquid with the separation matrix for a predetermined contact time.
Type:
Grant
Filed:
May 10, 2017
Date of Patent:
September 12, 2023
Assignee:
CYTIVA BIOPROCESS R&D AB
Inventors:
Annika Forss, Gustav José Rodrigo, Tomas Bjorkman, Mats Ander, Jesper Ulf Hansson
Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.
Type:
Grant
Filed:
October 12, 2020
Date of Patent:
September 12, 2023
Assignees:
Cytune Pharma, INSERM (Institut National de la Santé et de la Recherche Médicale)
Inventors:
Sebastien Daniel Morisseau, Geraldine Teppaz, Yannick Laurent Joseph Jacques, Bruno Gilbert Marc Robert, Guy Luc Michel De Martynoff, David Bechard
Abstract: An inhibitor of RNA polymerase II is described, wherein said inhibitor is selected a moiety which targets a protein selected from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C. Particular examples of such inhibitors are polypeptides expressed by a gene selected from IldD, IldR, nlpD or rfaH of a bacterial species, such as a commensal bacteria or asymptomatic carrier, or a variant of said protein. Inhibitors may be based upon bacterial Sigma S or NplD proteins. These inhibitors are useful in therapies, to suppress protein expression. Thus they may be used as immunosuppressants, anti-inflammatory or anti-infection agents.
Type:
Grant
Filed:
September 25, 2020
Date of Patent:
September 12, 2023
Inventors:
Catharina Svanborg, Nina Filenko, Ines Ambite
Abstract: The present invention to a method for expressing an exogenous gene specifically in cells of the retinal pigment epithelium of a primate, this method comprising the step of delivering an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or consisting of a nucleic acid sequence of at least 400 bp having at least 80% overall identity to the sequence of SEQ ID NO:1, to cells of the retinal pigment epithelium of the primate, wherein this isolated nucleic acid molecule specifically leads to the expression of an exogenous gene in cells of the retinal pigment epithelium of primates when a nucleic acid sequence coding for the exogenous gene is operatively linked to this isolated nucleic acid molecule.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
August 29, 2023
Assignee:
Friedrich Miescher Institute for Biomedical Research
Inventors:
Josephine Juettner, Jacek Krol, Botond Roska
Abstract: Methods for detecting and/or quantifying the potency of an agent using a cell-based assay are disclosed. A mammalian cell culture is grown upon a microelectrode array (MEA) which is used to measure an electrophysiological response of the mammalian cell culture. The cell culture is exposed to the agent, generally in at least two different dosages. The potency of the agent is detected by measuring a change in the electrophysiological responses associated with the at least two dosages when compared to a control condition. These changes can include the weighted mean firing rate (wMFR) and bursting of the cells.
Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.
Type:
Grant
Filed:
February 2, 2021
Date of Patent:
August 29, 2023
Inventors:
Michael T. Kowarik, Michael L. Wetter, Stefan J. Kemmler, Micha A. Häuptle, Veronica Gambillara, Manuela Mally
Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
Abstract: The present invention relates to anti-interleukin-36 receptor (anti-IL-36R1) antibody formulations for administration to a subject.
Type:
Grant
Filed:
March 5, 2020
Date of Patent:
August 22, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Sandra Nicole Denkinger, Anna Maria Steiner, Derrick Spencer Katayama, Rajni Prasad Mehra, Ingo Michael Presser, Ravija Singh, Sara Kay Wright
Abstract: Compositions for the treatment of colorectal cancer target bacterial biofilms in the gastrointestinal tract. Methods of treatment include one or more agents which target bacteria and the bacterial biofilms.
Type:
Grant
Filed:
February 28, 2019
Date of Patent:
August 22, 2023
Assignee:
The Johns Hopkins University
Inventors:
Cynthia L. Sears, Christine Craig, Drew M. Pardoll
Abstract: In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
Type:
Grant
Filed:
March 16, 2020
Date of Patent:
August 22, 2023
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response.
Type:
Grant
Filed:
October 29, 2019
Date of Patent:
August 8, 2023
Assignees:
INSERM (Instut National de la Santé et de la Recherche Médicale), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP)
Inventors:
Guy Gorochov, Martin Larsen, Delphine Sterlin, Jehane Fadlallah
Abstract: Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.
Type:
Grant
Filed:
January 5, 2018
Date of Patent:
August 8, 2023
Assignee:
Evaxion Biotech A/S
Inventors:
Niels Iversen Møller, Andreas Holm Mattsson
Abstract: Described herein are engineered microbe-targeting molecules, microbe-targeting articles, kits comprising the same, and uses thereof. Such microbe-targeting molecules, microbe-targeting articles, or the kits comprising the same can bind or capture of a microbe or microbial matter thereof, and can thus be used in various applications, such as diagnosis or treatment of an infection caused by microbes in a subject or any environmental surface.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
August 8, 2023
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Alexander L. Watters, Donald E. Ingber, Mark J. Cartwright, Michael Super, Martin Rottman, Evangelia Murray, Brendon Dusel